First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
Neda LaiteerapongJason T AlexanderLouis H PhilipsonAaron N WinnElbert S HuangPublished in: Annals of internal medicine (2023)